Europe stands at a critical moment as healthcare systems face growing pressure to accelerate patient access, adapt to more complex therapies, and remain competitive in a global innovation race increasingly shaped by the US and China. In this conversation, Iris Zemzoum discusses Europe’s readiness for next-generation therapies such as radioligand therapy (RLT), the need to reduce fragmentation across healthcare systems, and why faster access to innovation must become a shared priority across the healthcare ecosystem.
How has your medical and international leadership background shaped your perspective on healthcare and your approach to leading Europe for Novartis?
As a physician by training, I have always felt very connected to healthcare systems and to the realities patients and physicians face every day. Having worked both clinically and within the pharmaceutical industry gives you a practical understanding of patient journeys across different diseases and treatments, as well as the pressures physicians navigate within healthcare systems that can function very differently from one country to another. Over the course of my career, I have also had the opportunity to work across Europe, Asia Pacific, the Middle East, and Africa, and while those regions differ significantly in terms of healthcare structures, cultures, and levels of development, what ultimately remains constant is that healthcare always comes back to the patient and to improving outcomes for people.
One of the things that struck me most during my time outside Europe was the strong drive to move healthcare forward, often with a remarkable degree of agility, resilience, and creativity. Returning to Europe, I see a region with an extraordinary legacy in science, education, innovation, and clinical development, and in many ways all the foundations remain in place for Europe to continue shaping the future of healthcare globally. Europe has built that position over centuries, and we should not lose it at a moment when other regions are investing heavily in healthcare, biotechnology, and innovation. At a time when many European economies are under pressure and public spending priorities are increasingly competing with one another, we have an opportunity to reframe how we think about healthcare spending; viewing it as a long-term investment in the resilience, productivity, and wellbeing of societies not a cost to be contained.
I see us as an important partner within the broader healthcare ecosystem, working alongside governments, physicians, and healthcare systems to ensure innovation reaches patients faster and more effectively. Ultimately, when innovative medicines reach patients quickly, the impact extends far beyond individual treatment outcomes and contributes to stronger and healthier societies overall.
What role does Europe continue to play within Novartis’ global innovation, clinical development, and manufacturing strategy as global competition intensifies?
Europe remains deeply important for us at Novartis because of its longstanding strengths in science, innovation, clinical research, and healthcare infrastructure. We treat more than 43 million patients annually across the European Union and employ approximately 31,500 people across 76 sites, including our global headquarters in Switzerland. The region continues to play a major role in clinical development, manufacturing, and innovation, with extensive clinical trial activity across 25 countries involving around 25,000 patients. We have recently made some important strategic investments across Europe, not only because of the scientific capabilities that exist here, but also because of the depth of talent, institutions, and healthcare expertise across the region.
The global competitive environment, however, has changed considerably. The US and China have prioritized significant investments in healthcare, biotechnology, and innovation, backed by strategic intent; Europe needs to ensure it remains an attractive environment for continued investment and development. One of the key challenges is the fragmentation of healthcare and reimbursement systems across European countries. While Europe benefits from a centralised and trusted EMA, reimbursement and access decisions still take place nationally, often through highly complex and varied systems. Nevertheless, there is growing recognition across many markets that healthcare systems can evolve in ways that better serve patients and accelerate access to innovation.
According to the latest EFPIA WAIT Indicator, patients in Europe wait an average of 597 days between EMA approval and actual access through public healthcare systems, while only 28 percent of centrally approved medicines are fully available to patients across Europe. After years of clinical development and a positive scientific assessment, patients are often still waiting one or even two additional years for treatment depending on the country. For many patients, every day matters. That is why I believe there is an urgent need for greater collaboration across the healthcare ecosystem to redesign access pathways and reduce those delays through a shared commitment to providing access to medicine from day one following regulatory approval.
How can Europe accelerate patient access to innovative medicines while preserving national healthcare sovereignty and navigating fragmented healthcare systems?
Across Europe, there are already examples of systems that help accelerate access while maintaining national decision-making authority. Germany’s AMNOG framework, for example, allows medicines to become available following marketing authorisation while reimbursement and pricing negotiations continue in parallel. In Austria, “no-box” approvals allow physicians to apply for individual patient access outside the formal reimbursement system to address highly innovative medicines in the oncology, rare disease and gene therapy space. Belgium has also introduced the Early & Equitable Fast Access pathway earlier this year. While there is no perfect system, these examples show that more agile approaches are possible, even within very different national systems.
The broader challenge is that Europe still operates through highly fragmented reimbursement and regulatory structures, with significant variation between countries and, in some cases, even between regions within countries. Some healthcare systems require lengthy national reimbursement negotiations before access is granted. Greater alignment would clearly benefit patients by reducing delays and simplifying pathways to treatment. At the same time, healthcare systems across Europe remain deeply rooted in national sovereignty, and reimbursement decisions are closely tied to individual political priorities, healthcare structures, and budget realities. That fragmentation makes the system inherently complex.
In that context, I see the Joint Clinical Assessment presents a once-in-a-lifetime opportunity to establish a joint assessment framework that can help reduce duplication and bring life sciences innovation faster to patients in Europe. To succeed on this valuable shared ambition, the EU JCA first and foremost has to deliver an improvement versus today on time to patient access, and create a dynamic and pragmatic system with truly meaningful opportunities for stakeholder engagement throughout the process.
More broadly, Europe has historically been one of the world’s leading centres for science, innovation, and clinical development, but maintaining that position will require continued investment and an environment that appropriately values innovation while still ensuring patients can access medicines quickly and sustainably.
How is radioligand therapy testing the readiness of European healthcare systems for increasingly complex treatment platforms?
When I think about radioligand therapy, I see it almost as a litmus test for Europe’s healthcare systems and their ability to adapt to an entirely new generation of treatment platforms. These therapies require far more than scientific innovation alone. They depend on specialist infrastructure, diagnostic capacity, adapted safety and radioprotection frameworks, highly coordinated logistics, and close collaboration between hospitals, regulators, payers, and industry. In many ways, the broader question is whether healthcare systems are ready to integrate and scale therapies that operate very differently from traditional pharmaceutical models, particularly when they require entirely new ways of organising care delivery around patients.
That is where many of the current challenges emerge. Existing regulatory and operational frameworks were not originally designed for therapies such as RLT, which means there is a need to evolve reimbursement pathways, clinical assessment models, and regulatory approaches that still vary considerably across Europe. There is strong engagement from physicians, governments, and payers because the clinical value of these therapies is increasingly well recognised, but scaling capacity remains complex and requires close coordination across the healthcare ecosystem. France, for example, granted early access to RLT ahead of full reimbursement through its national early access framework, allowing eligible patients to receive treatment while the broader reimbursement process continued in parallel. That also helped healthcare systems prepare operationally by strengthening referral pathways, nuclear medicine capabilities, ordering processes, and treatment logistics before wider rollout.
The operational complexity behind RLT is significant because these therapies are produced on a patient-specific basis, have a very short usable window, and need to reach patients within a highly precise timeframe before the radioisotope decays. In some cases, there are only a few days between manufacturing and administration before the treatment is no longer usable. Manufacturing, logistics, hospital readiness, and treatment scheduling therefore all need to function seamlessly together. In addition, safety and radioprotection frameworks still differ significantly between countries, creating further operational complexity for hospitals implementing these therapies. Despite those challenges, our experience so far has been encouraging, and we continue to invest in Europe, where Novartis operates radioligand therapy manufacturing sites in Italy and Spain, and the production of radioactive isotopes in the Netherlands, while further sites are currently under development in France and Germany to support future demand. While the initial focus has been on prostate cancer and neuroendocrine tumours, the broader significance of RLT lies in what it reveals about how quickly healthcare systems can adapt to increasingly complex and highly specialised treatment platforms.
How important is it for pharmaceutical companies to remain closely connected to physicians and real-world clinical practice?
I think it is elementary, because while we develop and bring medicines to patients, physicians remain the closest interface to those patients and therefore one of the closest to understanding what patients truly need. They are often best positioned to identify which patients are most likely to benefit from a therapy, how treatments perform in clinical practice, and what impact they have not only in terms of efficacy, but also quality of life and tolerability.
For us, physicians therefore remain an extremely important source of insight, both during clinical development and later once medicines are available in the market. Maintaining that close relationship helps us better understand how therapies are reaching patients in real-world settings and how healthcare systems are adapting to increasingly complex treatment platforms. As innovation continues to evolve, staying closely connected to clinical practice becomes increasingly important in ensuring that new therapies are integrated effectively and sustainably into patient care.
What message would you send to European healthcare stakeholders at this important moment for innovation and patient access?
We speak a great deal about “day one access” because it is something I feel deeply passionate about, both as a physician and as chair of the European Markets Committee at the EFPIA. For me, the principle is straightforward: once a medicine has received regulatory approval, patients should be able to access it immediately while reimbursement and pricing discussions continue in parallel. Having worked in breast cancer research, enrolled patients into clinical trials, and treated patients directly, I have seen first-hand how transformative innovative therapies can be, whether in extending survival or improving quality of life. That is why I believe we should not lose additional time once years of clinical development and rigorous regulatory assessment have already established the value of a medicine.
Today, even after approval from the EMA, patients across Europe can still wait many months, and sometimes years, before gaining access through public healthcare systems. Those delays are often linked to pricing and reimbursement negotiations, but I do not believe those discussions should come at the expense of patients waiting for treatment. We already have examples across Europe showing that earlier access can coexist with ongoing negotiations, and I believe we should build much more consistently on those models.
Ultimately, there is a shared interest across industry, governments, physicians, and healthcare systems in ensuring patients receive timely access to innovation, and I remain convinced that with openness and collaboration, we can significantly shorten those timelines without compromising the broader process, scientific rigour, or assessment standards.

